Genmab A/S (GMAB) NASDAQ
23.85
-1.6(-6.29%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Genmab A/S
Sector
Healthcare
Industry
Biotechnology
Employees
2638
First IPO Date
June 01, 2009
Key Executives
| Name | Title | Pay | Year Born |
| Jan van de Winkel | Co-Founder, President & Chief Executive Officer | 3.3M | 1961 |
| Takahiro Hamatani | Senior Director of Finance Japan & Non-Independent Director | 100,000 | 1975 |
| Martin Schultz | Senior Director, Head of Development Business Partnership & Strategy and Director | 300,000 | 1975 |
| Mijke Zachariasse | Vice President, Head of Antibody Research Materials & Director | 300,000 | 1973 |
| Christopher Cozic | Executive Vice President & Chief People Officer | 800,000 | 1979 |
| Martine J. van Vugt | Executive Vice President & Chief Strategy Officer | 900,000 | 1971 |
| Anthony Pagano | Executive Vice President & Chief Financial Officer | 1.1M | 1978 |
| Tahamtan Ahmadi | Executive Vice President, Chief Medical Officer & Head of Experimental Medicines | 1.3M | 1973 |
| Judith V. Klimovsky | Executive Vice President & Chief Development Officer | 1.3M | 1958 |
| Gregory David Emil Mueller | Executive VP, General Counsel & Chief Legal Officer | 1.7M | 1971 |
| Rayne Waller | Executive Vice President & Chief Technical Operations Officer | 1.8M | 1968 |
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
